Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

References

• Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr., Lifson JD, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277–12. doi:https://doi.org/10.1038/nature12746.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–28. doi:https://doi.org/10.1038/nature12744.
   PubMed Web of Science ®Google Scholar
• Julg B, Pegu A, Abbink P, Liu J, Brinkman A, Molloy K, Mojta S, Chandrashekar A, Callow K, Wang K, et al. Virological control by the CD4-binding site antibody N6 in simian-human immunodeficiency virus-infected rhesus monkeys. J Virol. 2017;91(16). doi:https://doi.org/10.1128/JVI.00498-17
   Google Scholar
• Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A. 2013;110(41):16538–43. doi:https://doi.org/10.1073/pnas.1315295110.
   PubMedGoogle Scholar
• Bolton DL, Pegu A, Wang K, McGinnis K, Nason M, Foulds K, Letukas V, Schmidt SD, Chen X, Todd JP, et al. Human immunodeficiency virus type 1 monoclonal antibodies suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-associated viral reservoirs. J Virol. 2016;90(3):1321–32. doi:https://doi.org/10.1128/JVI.02454-15.
   PubMedGoogle Scholar
• Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206. doi:https://doi.org/10.1126/scitranslmed.aad5752.
   PubMed Web of Science ®Google Scholar
• Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556–60. doi:https://doi.org/10.1038/nature18929.
   PubMed Web of Science ®Google Scholar
• Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185–91. doi:https://doi.org/10.1038/nm.4268.
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr., Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487–91. doi:https://doi.org/10.1038/nature14411.
   PubMed Web of Science ®Google Scholar
• Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 2012;109(46):18921–25. doi:https://doi.org/10.1073/pnas.1214785109.
   PubMed Web of Science ®Google Scholar
• Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88. doi:https://doi.org/10.1126/scitranslmed.3008992.
   PubMed Web of Science ®Google Scholar
• Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669–82. doi:https://doi.org/10.1128/JVI.02213-14.
   PubMed Web of Science ®Google Scholar
• Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014;211(10):2061–74. doi:https://doi.org/10.1084/jem.20132494.
   PubMed Web of Science ®Google Scholar
• Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, Ko SY, Chen X, Schmidt SD, Haase AT, et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol. 2015;89(11):5895–903. doi:https://doi.org/10.1128/JVI.00210-15.
   PubMed Web of Science ®Google Scholar
• Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016;533(7601):105–09. doi:https://doi.org/10.1038/nature17677.
   PubMed Web of Science ®Google Scholar
• Moldt B, Le KM, Carnathan DG, Whitney JB, Schultz N, Lewis MG, Borducchi EN, Smith KM, Mackel JJ, Sweat SL, et al. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. AIDS. 2016;30(10):1543–51. doi:https://doi.org/10.1097/QAD.0000000000001102.
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019;25(4):547–53. doi:https://doi.org/10.1038/s41591-019-0412-8.
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol. 2016;90(1):76–91. doi:https://doi.org/10.1128/JVI.01791-15.
   PubMedGoogle Scholar
• Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity. 2016;45(5):1108–21. doi:https://doi.org/10.1016/j.immuni.2016.10.027.
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies [Research Support, N.I.H., Extramural research support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Nature. 2011;477(7365):466–70. doi:https://doi.org/10.1038/nature10373.
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. doi:https://doi.org/10.1126/science.1187659.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 2013;39(2):245–58. doi:https://doi.org/10.1016/j.immuni.2013.04.012.
   PubMedGoogle Scholar
• West AP Jr., Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A. 2012;109(30):E2083–90. doi:https://doi.org/10.1073/pnas.1208984109.
   PubMedGoogle Scholar
• van de Bovenkamp FS, Derksen NIL, van Breemen MJ, de Taeye SW, Ooijevaar-de Heer P, Sanders RW, Rispens T. Variable domain N-linked glycans acquired during antigen-specific immune responses can contribute to immunoglobulin G antibody stability. Front Immunol. 2018;9:740. doi:https://doi.org/10.3389/fimmu.2018.00740.
   PubMedGoogle Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–59. doi:https://doi.org/10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Meyers NL, Larsson M, Vorrsjo E, Olivecrona G, Small DM. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition. J Lipid Res. 2017;58(5):840–52. doi:https://doi.org/10.1194/jlr.M071126.
   PubMed Web of Science ®Google Scholar
• Li L, Vorobyov I, Allen TW. The different interactions of lysine and arginine side chains with lipid membranes. J Phys Chem B. 2013;117(40):11906–20. doi:https://doi.org/10.1021/jp405418y.
   PubMed Web of Science ®Google Scholar
• Shehata L, Maurer DP, Wec AZ, Lilov A, Champney E, Sun T, Archambault K, Burnina I, Lynaugh H, Zhi X, et al. Affinity maturation enhances antibody specificity but compromises conformational stability. Cell Rep. 2019;28(13):3300–3308 e4. doi:https://doi.org/10.1016/j.celrep.2019.08.056.
   PubMed Web of Science ®Google Scholar
• Chuang GY, Zhang B, McKee K, O’Dell S, Kwon YD, Zhou T, Blinn J, Lloyd K, Parks R, Von Holle T, et al. Eliminating antibody polyreactivity through addition of N-linked glycosylation. Protein Sci. 2015;24(6):1019–30. doi:https://doi.org/10.1002/pro.2682.
   PubMedGoogle Scholar
• Kwon Y, Chuang GY, Zhang B, Bailer RT, Doria-Rose NA, Gindin TS. Surface-matrix screening identifies semi-specific interactions that improve potency of a near pan-reactive HIV-1-neutralizing antibody. Cell Rep. 2018;22(7):1798–809. doi:https://doi.org/10.1016/j.celrep.2018.01.023.
   PubMedGoogle Scholar
• Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308(5730):1906–08. doi:https://doi.org/10.1126/science.1111781.
   PubMed Web of Science ®Google Scholar
• Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131–46. doi:https://doi.org/10.1016/j.jim.2013.11.022.
   PubMed Web of Science ®Google Scholar
• Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013;340(6133):751–56. doi:https://doi.org/10.1126/science.1233989.
   PubMedGoogle Scholar
• Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, Tong T, Li J, Nagarajan R, Ozorowski G, Ambrozak DR, et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity. 2017;46(5):777–791 e10. doi:https://doi.org/10.1016/j.immuni.2017.04.011.
   PubMedGoogle Scholar
• Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18(12):1759–69. doi:https://doi.org/10.1093/intimm/dxl110.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol. 2010;602:93–104. doi:https://doi.org/10.1007/978-1-60761-058-8_6.
   PubMedGoogle Scholar
• Ivleva VB, Cooper JW, Arnold FJ, Lei QP. Overcoming challenges in structural characterization of HIV-1 Envelope glycoprotein by LC-MS/MS. J Am Soc Mass Spectrom. 2019;30(9):1663–78. doi:https://doi.org/10.1007/s13361-019-02225-3.
   PubMedGoogle Scholar